Can Men Take D-Mannose for UTIs? What the Evidence Shows

D-mannose is safe for men to take, and the biological mechanism behind it applies regardless of sex. The sugar works by blocking the adhesion of certain bacteria to the urinary tract lining, a process that happens the same way in male and female bladders. The catch is that virtually all clinical trials of D-mannose for UTIs have been conducted in women, so the direct evidence in men is thin. That gap matters more than it might seem, because male UTIs tend to differ from female UTIs in cause, severity, and the mix of bacteria involved.

Why Male UTIs Are a Different Problem

UTIs are far less common in men than in women, which is why the research has focused elsewhere. Men under 50 rarely develop them, but lifetime risk is still a meaningful 14%, and that risk climbs with age. Older men dealing with prostate enlargement, catheter use, or reduced bladder emptying face significantly higher odds. When a UTI does occur in a man, clinicians typically classify it as “complicated” because the male anatomy makes simple bladder infections less likely and infections involving deeper structures more common.

The bacterial landscape in male UTIs overlaps substantially with female UTIs but is not identical. In a large French study spanning 2019 to 2023, E. coli was the leading pathogen in male UTIs at about 40%, followed by E. faecalis at around 13% and Klebsiella pneumoniae at roughly 8%.¹ A Bangladeshi study of 200 male urine samples found E. coli even more dominant, accounting for about half of positive cultures.² That means E. coli is the primary culprit in men as it is in women, but a larger share of male infections are caused by organisms D-mannose does not target. This distinction is central to understanding how useful D-mannose can realistically be for men.

How D-Mannose Interferes with Infection

D-mannose is a simple sugar, closely related to glucose, that the body absorbs but barely metabolizes. Most of an oral dose passes through the kidneys and concentrates in the urine within a couple of hours. Once there, it acts as a decoy. The strains of E. coli responsible for most UTIs carry tiny hair-like projections called type 1 pili, tipped with a protein called FimH. Under normal circumstances, FimH latches onto sugar-coated proteins lining the bladder wall, anchoring the bacteria in place and kicking off infection. D-mannose in the urine competes for that same binding site, essentially tricking the bacteria into grabbing onto free-floating sugar molecules instead of the bladder lining.³ Bacteria that can’t adhere get flushed out the next time you urinate.

This mechanism is specific to type 1 pili. It does not work against all strains of E. coli and does not work against most other bacteria. In lab tests, D-mannose prevented type 1 adhesion but had no effect on P-type adhesion, a different attachment strategy used by some uropathogenic E. coli strains that target the kidneys.⁴ In practical terms, D-mannose is most relevant for lower urinary tract infections caused by type 1 pili-bearing E. coli. Nothing about this mechanism is sex-specific. The bladder lining in men has the same mannosylated proteins that FimH targets in women. If D-mannose blocks bacterial adhesion in a female bladder, it should do the same in a male one.

What the Clinical Trials Actually Show

Here is where the evidence becomes frustrating for men looking for clear answers. A Cochrane systematic review on D-mannose for preventing and treating UTIs found that early pilot studies in both animals and humans tested concentrated D-mannose at doses ranging from 200 mg up to 2 to 3 grams and reported possible benefits in reducing symptoms or recurrence.⁵ However, these trials overwhelmingly enrolled women with recurrent uncomplicated UTIs. The Cochrane reviewers noted that the overall certainty of the evidence was low, and no male-specific data were highlighted.

A non-interventional study comparing D-mannose to antibiotics for acute lower UTIs suggested D-mannose might perform comparably, but again, the study population was predominantly female with uncomplicated infections.⁶ A narrative review concluded that D-mannose is a promising alternative or complementary approach for recurrent UTI prevention, largely because it blocks the primary attachment mechanism of E. coli.⁷ Promising, but still without the male-specific trial data that would let a doctor say with confidence, “This is proven to work in men.”

The absence of male data does not mean D-mannose is ineffective for men. It means the question has not been tested rigorously in that population. Given that the mechanism is anatomically agnostic and that E. coli causes a substantial share of male UTIs, many urologists consider it a reasonable thing to try, particularly for prevention. But the honest answer is that the evidence base is extrapolated from women, not established directly in men.

Where D-Mannose Falls Short in Men

Several features of male UTIs limit D-mannose’s usefulness in ways that don’t apply as strongly in women. First, a larger proportion of male UTIs are caused by non-E. coli pathogens. If your infection is driven by Enterococcus faecalis, Pseudomonas aeruginosa, or Klebsiella, D-mannose has no established mechanism against them. The French epidemiological data show that roughly 60% of male UTI pathogens are something other than E. coli, compared to a much smaller share in women.¹ That means D-mannose’s theoretical ceiling of benefit is lower in men from the start.

Second, male UTIs are more frequently complicated. An infection linked to an enlarged prostate, a kidney stone, or a catheter involves tissue beyond the bladder surface. D-mannose works by preventing adhesion to the bladder lining, which is helpful for a simple cystitis. It is far less likely to resolve a prostate infection or an upper tract infection once bacteria have already invaded tissue. UTIs can occasionally progress to urosepsis, which accounts for roughly a quarter of all sepsis cases and requires aggressive medical treatment.⁸ D-mannose is not a substitute for antibiotics in any serious or systemic infection.

Third, the anti-biofilm data are mixed. Lab studies show that D-mannose reduces E. coli biofilm mass and disrupts initial adhesion, which is relevant for catheter-associated infections.⁹ One in-vitro study found that D-mannose cut E. coli biofilm biomass by nearly half, but the same study observed that it actually increased biofilm growth for S. aureus.¹⁰ So for catheterized men dealing with mixed-organism infections, D-mannose could theoretically help against one pathogen while making conditions slightly more hospitable for another. This is speculative lab data, not clinical evidence, but it underscores why D-mannose is not a blanket solution.

Combining D-Mannose with Cranberry or Antibiotics

Some of the more encouraging research involves pairing D-mannose with other agents rather than using it alone. Cranberry extract targets a different adhesion pathway, blocking the P-type pili that D-mannose misses.⁴ Together, the two supplements cover both major attachment strategies used by uropathogenic E. coli. A systematic review found that combination non-antibiotic products tended to produce more consistent results in reducing the number of symptomatic UTIs or relieving symptoms in women.¹¹

An intriguing pilot study tested the combination of cranberry extract and D-mannose alongside antibiotics during acute UTI episodes. Cure rates at day seven were higher when the combination product was added to the antibiotic compared to antibiotics alone. The most striking finding involved antibiotic-resistant strains: the cure rate jumped to nearly 89% with the combination product versus under 38% with the antibiotic alone.¹² The researchers speculated that disrupting bacterial adhesion might make resistant bacteria more vulnerable to the antibiotic. This is a single pilot study and the results need replication, but the direction is interesting for anyone dealing with resistant infections, a growing concern in men and women alike.

A recent pilot study also looked at D-mannose combined with proanthocyanidins for preventing postcoital recurrent UTIs in young women, finding the combination safe, well tolerated, and promising.¹³ Again, no male data, but the safety profile extends to these combination formulations.

Dosing, Safety, and What to Expect

D-mannose is sold as a powder, capsule, or tablet and is available over the counter in most countries. The doses used in published studies range from 200 mg to 2 to 3 grams, with the most common prevention protocol being about 2 grams dissolved in water, taken once or twice daily.⁵ For acute episodes, some protocols call for higher or more frequent doses in the first few days. There is no universally agreed-upon regimen, and optimal dosing has not been determined through large-scale trials.¹⁴

Side effects are generally mild. The most commonly reported issues are bloating, loose stools, and mild diarrhea, which tend to resolve with dose adjustment. Because D-mannose is a sugar, people with diabetes sometimes worry about blood glucose effects. Interestingly, animal research has found that D-mannose may actually improve fasting blood glucose levels and insulin sensitivity, at least in diabetic mice, rather than worsening glycemic control.¹⁵ That said, human data on this front are limited, and anyone on diabetes medications should mention D-mannose to their doctor. The sugar is absorbed but largely excreted unchanged, which is why it concentrates in the urine rather than spiking blood sugar the way glucose would.

When a Man Should Skip D-Mannose and See a Doctor

Because male UTIs are more often complicated than female ones, the threshold for medical evaluation should be lower. Any of the following situations call for prompt medical care rather than self-treatment with a supplement:

Fever or back pain: These suggest the infection may have moved beyond the bladder to the kidneys or prostate.
First-time UTI: Men who have never had a UTI should get a proper workup. A first infection may signal an underlying structural issue, prostate problem, or other condition worth diagnosing.
Urinary retention: Difficulty emptying the bladder completely is common with prostate enlargement and creates conditions D-mannose cannot fix on its own.
Catheter in place: Catheter-associated infections involve biofilms and mixed organisms, requiring targeted antibiotic treatment.
Blood in the urine: In men, especially those over 50, visible blood warrants investigation for causes beyond a simple infection.

D-mannose is best suited for men who have had a confirmed E. coli UTI, recovered with antibiotics, and want to reduce the chance of recurrence. Using it as a preventive supplement alongside adequate hydration makes biological sense and carries little risk. Using it as a sole treatment for an active infection in a man is riskier, because the probability that the infection is complicated or caused by a non-E. coli organism is higher than it would be in a young woman with straightforward cystitis.

The Antibiotic Resistance Angle

One of the more practical reasons men might consider D-mannose is the growing problem of antibiotic-resistant UTIs. The French epidemiological study that tracked male UTIs from 2019 to 2023 documented resistance patterns among the bacterial isolates, a reminder that the antibiotics used for UTIs are not infinitely reliable.¹ Each course of antibiotics carries a small but real risk of selecting for resistant organisms, both in the urinary tract and in gut bacteria. For men with recurrent UTIs who are cycling through antibiotic prescriptions, a preventive supplement that reduces the frequency of infections, even modestly, can reduce overall antibiotic exposure over time.

This is the context in which D-mannose gets the most traction in the clinical literature: not as a miracle cure, but as one piece of a strategy to keep UTIs from happening in the first place so that antibiotics can be reserved for when they are truly needed.⁷ For a man who keeps getting E. coli UTIs and is tired of repeated antibiotic courses, adding D-mannose to a daily routine is low-cost, low-risk, and mechanistically sound. Just don’t expect it to replace medical evaluation or treatment when an active infection is already underway.

D-Mannose Beyond the Urinary Tract

Research on D-mannose has branched into areas well beyond UTI prevention, which may be relevant for men considering long-term supplementation. The animal study mentioned earlier found that D-mannose improved glucose tolerance and insulin sensitivity in diabetic mice, with additional protective effects on organs commonly damaged by diabetes.¹⁵ Separate lines of research, mostly preclinical, have explored D-mannose’s effects on immune regulation and inflammation. None of this is ready for clinical recommendations, but it does suggest that D-mannose supplementation is unlikely to be harmful over extended periods, and it may eventually prove to have benefits beyond the bladder. For now, those additional benefits remain unproven in humans, and the urinary tract remains the most evidence-supported reason to take it.

1
Infectious Diseases Now. Bacterial epidemiology and antibiotic resistance rates in male urinary tract infections in France, 2019–2023
2
Central Medical College Journal. Prevalence and Antibiogram of Escherichia Coli Isolated from Urine Sample of Male UTI Patient
3
PubMed Central. Considerations on D-mannose Mechanism of Action and Consequent Classification of Marketed Healthcare Products
4
PubMed. Differences in P-Type and Type 1 Uropathogenic Escherichia coli Urinary Anti-Adhesion Activity of Cranberry Fruit Juice Dry Extract Product and D-Mannose Dietary Supplement
5
PubMed Central. D‐mannose for preventing and treating urinary tract infections
6
PubMed Central. Why d-Mannose May Be as Efficient as Antibiotics in the Treatment of Acute Uncomplicated Lower Urinary Tract Infections-Preliminary Considerations and Conclusions from a Non-Interventional Study
7
PubMed Central. Role of D-mannose in urinary tract infections – a narrative review
8
PubMed Central. Approach to a patient with urosepsis
9
Research and Reports in Urology. Catheter-Associated Urinary Tract Infections: Current Challenges and Future Prospects
10
Izvestia Ufimskogo Nauchnogo Tsentra RAN. D-MANNOSE EFFECTS ON ADHESION, METABOLIC ACTIVITY AND BIOFILM FORMATION OF UROPATHOGENIC MICROORGANISMS
11
PubMed Central. The Clinical Trial Outcomes of Cranberry, D-Mannose, and NSAIDs in the Prevention or Management of Uncomplicated Urinary Tract Infections in Women: A Systematic Review
12
PubMed Central. Combination of cranberry extract and D-mannose – possible enhancer of uropathogen sensitivity to antibiotics in acute therapy of urinary tract infections: Results of a pilot study
13
PubMed. MANCOIT study: Pilot study on the prevention of recurrent postcoital urinary tract infection in women with d-mannose plus proanthocyanidins (PAC)
14
PubMed Central. The Molecular Mechanisms and Therapeutic Potential of Cranberry, D-Mannose, and Flavonoids against Infectious Diseases: The Example of Urinary Tract Infections
15
PubMed Central. D‐Mannose Alleviates Type 2 Diabetes and Rescues Multi‐Organ Deteriorations by Controlling Release of Pathological Extracellular Vesicles